Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Västra Hamnen Market Focus: Lipum: On track for completing phase I

Lipum

• Promising interim data in the phase I study
• Raised a net of MSEK 73 and received a loan commitment of MSEK 20
• Awaiting the final read-out, we keep our fair value at SEK 10.81 per share

In Lipum’s Q2 report, CEO Ola Sandborgh repeated that he expects to complete the phase I study with SOL-116 during the second half of 2024. Interim results indicate that the study will meet its primary safety and tolerability endpoints. The drug candidate has also shown expected and preferred pharmacokinetics. Currently, the last group including rheumatoid arthritis patients is about to be concluded.

We maintain our model assumptions until the phase I study is completed. Therefore, we keep our risk-adjusted fair value at SEK 10.81 per share for now. The full report is available here.

About Market Focus


The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.